Altimmune, Inc. - ALT STOCK NEWS

AVG Group Sarl has made a strategic investment of approximately NOK 80,000,000 in Alternus Energy Group PLC, bolstering its position in the Nordic renewable energy sector. Alternus aims to become one of the largest pan-European solar operators by the end of the decade. This partnership will enable AVG to provide further financing and expertise in solar technology, enhancing Alternus's operations in Norway. Currently, Alternus has a portfolio of 39 solar parks with over 140 MWp capacity and plans to acquire an additional 1.2 GW of projects by 2023, aiming for over 2 GW by 2025.

Altimmune, Inc. (Nasdaq: ALT) announced results from its Phase 1b trial evaluating the safety and immunogenicity of its intranasal anthrax vaccine candidate, NasoShield. The trial, supported by BARDA, involved 42 healthy volunteers. Key findings indicated significant serum binding antibody responses to the protective antigen compared to placebo. However, responses blocking anthrax toxin were lower than in previous studies with BioThrax. Importantly, 80% of subjects exhibited mucosal IgA responses. The vaccine was well-tolerated. Next steps will involve discussions with BARDA regarding further development funding.

Altimmune, Inc. (Nasdaq: ALT) announced a collaboration with Summit Biosciences to manufacture a metered multidose nasal spray for its COVID-19 vaccine candidate, AdCOVID. This innovation aims to provide an easy vaccination method, especially in high-demand areas, benefiting from room temperature stability. Currently in a Phase 1 trial, AdCOVID is designed to generate systemic and mucosal immunity against SARS-CoV-2. Positive results from preclinical studies show strong immune responses and high protection rates.

Altimmune, Inc. (Nasdaq: ALT) announced promising preclinical results for its intranasal COVID-19 vaccine candidate, AdCOVID. Conducted in collaboration with the University of Alabama at Birmingham and Saint Louis University, the studies demonstrated 100% protection against lethal SARS-CoV-2 challenges in mice and over a 1000-fold reduction in viral replication post-infection. Antibody responses were durable for at least six months. The Phase 1 clinical trial has begun with data expected in Q2 2021, highlighting AdCOVID’s potential as a leading vaccine candidate.

Altimmune, Inc. expands its collaboration with Lonza to establish a dedicated suite for the production of its AdCOVID vaccine candidate at Lonza's Houston facility. This agreement aims to enhance manufacturing capacity for the intranasal COVID-19 vaccine, addressing current supply challenges. Altimmune is in Phase 1 trials of AdCOVID, with data expected in Q2 2021. The vaccine promises easy storage and a potential one-year immunity after a single dose. Preclinical studies suggest significant immune response activation, positioning AdCOVID as a potential leader in COVID-19 vaccination strategies.

Altimmune announced management presentations at two upcoming conferences. A fireside chat at the H.C. Wainwright Global Life Sciences Conference will take place on March 9, 2021, featuring CEO Vipin Garg and other executives. Additionally, Chief Medical Officer Dr. Scott Harris will present at the NASH-TAG Conference on March 13, 2021, discussing dual GLP-1 agonists for treating liver dysfunction in NASH. Webcast links for both events are available on Altimmune's website, providing further insights into their innovative pipeline.

Altimmune, Inc. (Nasdaq: ALT) has initiated enrollment in a Phase 1 clinical trial for AdCOVID, a single-dose intranasal COVID-19 vaccine aimed at generating both systemic and local immunity. The trial targets up to 180 healthy adults aged 18-55 to assess safety and immunogenicity. Results from preclinical studies show promising mucosal immunity responses, crucial for virus transmission prevention. The trial's full data readout is expected by Q2 2021, with the potential for room temperature stability enhancing distribution efficiency.

Altimmune announced the commencement of enrollment in its Phase 1 clinical trial for AdCOVID, a novel intranasal COVID-19 vaccine. The company reported a significant increase in cash reserves to $216 million, up from $37 million year-over-year. Revenue rose to $8.2 million, driven by U.S. government contracts. However, net loss attributed to common stockholders increased to $49 million, reflecting higher R&D and administrative expenses. The company is advancing multiple clinical trials, including ALT-801 and T-COVID, with data readouts expected in 2021.

Altimmune plans to report its full year 2020 financial results on February 25, 2021. The company will hold a conference call at 8:30 AM ET to discuss these results and provide a business update. Altimmune focuses on developing intranasal vaccines and immune modulating therapies, with a diverse pipeline including products for COVID-19, anthrax, influenza, and liver disease. The company's offerings include AdCOVID™, NasoShield™, NasoVAX™, T-COVID™, ALT-801, and HepTcell™.